Robert Alan Kloner, MD, PhD

Professor of Medicine (Clinical Scholar)

Is this your profile? Click to edit

Awards

Alpha Omega Alpha: Member, 1973
Merck: Award for Outstanding Achievement in the Study of Medicine, 1975
American Society of Clinical Pathologists: Sheard-Sanford Award for Meritorius Original Student Research in Pathology During Medical School, 1976
American Heart Association: Recipient of the Established Investigatorship Award, 1981
– 1986
American College of Physicians: Research Prize, 1988
82nd Annual Scientific Assembly of the Southern Medical Association: Scientific Exhibit Achievement Award, 1988
American Society for Clinical Investigation: Elected Member, 1990
American Heart Association: Continuing Service Award, 1991
NIH: Cardiovascular Study Section A, 1995
– 1998
United States Israel Binational Science Foundation: The Henry N. Neufeld Memorial Award, 1996
American Heart Association: Inaugural Fellow of the Council on Basic Cardiovascular Sciences, 2001
Institute for Scientific Information: Identified as one of the world’s most highly cited authors, 2002
Good Samaritan Hospital: Physician Leadership Award, 2003
Consumer’s Research Council of America: Listed in Guide to America’s Top Cardiologists, 2007

Mesenchymal Stem Cells for Myocardial Infarction
NIH · R01HL073709 · Jul 15, 2003 – Jun 30, 2008 · Role: Principal Investigator
Biologic Ventricular Assist Device
NIH · R21HL071965 · Sep 30, 2002 – Jul 31, 2006 · Role: Principal Investigator
MODERATE ALCOHOL EFFECT ON CARDIAC ISCHEMIA
NIH · R03AA012258 · Jul 1, 1999 – Jun 30, 2001 · Role: Principal Investigator
COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
NIH · R01HL061488 · Jan 11, 1999 – Dec 31, 2004 · Role: Principal Investigator

Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction? J Cardiovasc Pharmacol Ther. 2019 05; 24(3):215-224. Allencherril J, . View in PubMed
A Thank You From the Editor-in-Chief. J Cardiovasc Pharmacol Ther. 2019 01; 24(1):90-91.. View in PubMed
Cardiovascular effects of marijuana. Trends Cardiovasc Med. 2019 10; 29(7):403-407.. View in PubMed
Acute and Subacute Triggers of Cardiovascular Events. Am J Cardiol. 2018 12 15; 122(12):2157-2165.. View in PubMed
The Case for Takotsubo Cardiomyopathy (Syndrome) as a Variant of Acute Myocardial Infarction. Circulation. 2018 08 28; 138(9):855-857.. View in PubMed
Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors. J Cardiovasc Pharmacol Ther. 2018 11; 23(6):524-531.. View in PubMed
The pharmacist’s role in improving the treatment of erectile dysfunction and its underlying causes. Res Social Adm Pharm. 2019 05; 15(5):591-599.. View in PubMed
Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. Sex Med Rev. 2018 10; 6(4):583-594.. View in PubMed
No-reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol. 2018 09 01; 315(3):H550-H562.. View in PubMed
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. J Cardiovasc Pharmacol Ther. 2018 09; 23(5):375-386.. View in PubMed